A Challenge Towards the Next-Generation Standard Treatment for AML

The National Cancer Institute (NCI) is leading a precision medicine initiative called MyeloMATCH, and as part of this, a new Phase 2 clinical trial (NCT05554393) is actively recruiting patients with younger, intermediate-risk Acute Myeloid Leukemia (AML). This trial, which began on September 19, 2024, aims to be completed by December 2027, and represents an attempt to overcome the limitations of traditional chemotherapy, which has been used as a standard treatment for decades. The trial specifically targets the intermediate-risk group, where relapse rates are high and treatment outcomes are uncertain, even in younger patients, demonstrating a shift in treatment paradigms towards providing precise, personalized treatment from the early stages. The core of this trial is to improve treatment efficacy by adding targeted therapies to the existing 7+3 regimen of cytarabine and daunorubicin.

Multi-Target Mechanism Aiming for Synergy

The clinical trial randomly assigns patients to three treatment groups to compare their effectiveness. The first group receives the existing standard chemotherapy regimen of cytarabine and daunorubicin alone, while the second group receives this regimen plus venetoclax (Venclexta), a BCL-2 inhibitor from AbbVie. The third group receives a combination of azacitidine (Vidaza), a DNA methyltransferase inhibitor from Bristol Myers Squibb (BMS) that releases the abnormal gene suppression in cells, and venetoclax. Each drug is designed to stimulate different pathways of cancer cell death, overcoming resistance and creating a synergistic effect. In particular, by blocking the proteins that prevent cancer cells from dying and simultaneously interfering with DNA replication, the trial aims to more fundamentally kill leukemia cells.

New Clinical Design Focused on Minimal Residual Disease (MRD)

The primary endpoint of this trial is the rate of achievement of measurable residual disease (MRD) negativity in patients who achieve complete remission (CR). This represents a more advanced criterion that goes beyond the conventional assessment of simple remission, tracking even the smallest remaining cancer cells in the body to determine treatment success. The trial strictly selects patients aged 18 to 59 with newly diagnosed AML who have relatively favorable or non-poor genetic mutations. This precise clinical design can be used as a strong, objective indicator to demonstrate the actual relapse prevention effect of leukemia in the regulatory approval process.

Potential for Reshaping the AML Treatment Market and Competitive Landscape

The global AML treatment market is currently estimated at approximately $3.8 billion (approximately 5 trillion Korean Won) as of 2025 and is growing rapidly each year. Venetoclax is a blockbuster drug co-developed by AbbVie and Genentech, a subsidiary of Roche, and azacitidine is a leading anticancer drug from BMS. Although this trial is a public-interest trial led by the government, its success is expected to contribute significantly to the expansion of indications and increased sales for these companies. In particular, if it replaces the existing first-line standard treatment regimen, the market dominance of these pharmaceutical companies will inevitably be strengthened to a monopolistic level.